AdultPediatricGeriatricDosage Forms & Strengths capsule: Schedule IV 5mg 10mg 25mg Anxiety Mild/moderate: 5-10 mg PO q6-8hr Severe: 20-25 mg PO q6-8hr Preoperative Apprehension & Anxiety 5-10 mg PO q6-8hr Dosing Modifications Renal impairment CrCl <10 mL/min: 50% of recommended dose CrCl >10 mL/min: Dose adjustment not necessary (monitor) Hepatic impairment Not studied Dosage Forms & Strengths capsule: Schedule IV 5mg 10mg 25mg Anxiety <6 years: Safety and efficacy not established >6 years: 5 mg PO BID/QID; may increase dose to 10 mg PO BID/TID if necessaryAnxiety Lower initial dose: 5 mg PO q6-12hr; adjust gradually based on response and incidence of adverse effects Dosing Considerations Adjust for renal impairment; administer 50% of recommended dose if CrCl <10 mL/min Not drug of choice in elderly because of prolonged sedation and increased risk of falls/fracturesInteraction CheckerEnter a drug name and chlordiazepoxideNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (24)abametapirabametapir will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.apalutamideapalutamide will decrease the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, chlordiazepoxide. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.benzhydrocodone/acetaminophen and chlordiazepoxide both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine subdermal implantbuprenorphine subdermal implant and chlordiazepoxide both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine transdermalbuprenorphine transdermal and chlordiazepoxide both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine, long-acting injectionbuprenorphine, long-acting injection and chlordiazepoxide both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatecalcium/magnesium/potassium/sodium oxybateschlordiazepoxide, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.conivaptanconivaptan will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.dacomitinibdacomitinib will increase the level or effect of chlordiazepoxide by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. enzalutamideenzalutamide will decrease the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.fexinidazolefexinidazole will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.hydrocodonehydrocodone, chlordiazepoxide. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.idelalisibidelalisib will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesivosidenibivosidenib will decrease the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.lonafarniblonafarnib will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.metoclopramide intranasalchlordiazepoxide, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.nefazodonenefazodone will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.olopatadine intranasalchlordiazepoxide and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. selinexorselinexor, chlordiazepoxide. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sodium oxybatechlordiazepoxide, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sufentanil SLsufentanil SL, chlordiazepoxide. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tucatinibtucatinib will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.valerianvalerian and chlordiazepoxide both increase sedation. Avoid or Use Alternate Drug.voxelotorvoxelotor will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.Monitor Closely (247)abirateroneabiraterone increases levels of chlordiazepoxide by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.acrivastineacrivastine and chlordiazepoxide both increase sedation. Use Caution/Monitor.albuterolchlordiazepoxide increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanilchlordiazepoxide and alfentanil both increase sedation. Use Caution/Monitor.alprazolamalprazolam and chlordiazepoxide both increase sedation. Use Caution/Monitor.amisulprideamisulpride and chlordiazepoxide both increase sedation. Use Caution/Monitor.amitriptylinechlordiazepoxide and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and chlordiazepoxide both increase sedation. Use Caution/Monitor.amobarbital will decrease the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.amoxapinechlordiazepoxide and amoxapine both increase sedation. Use Caution/Monitor.apomorphinechlordiazepoxide and apomorphine both increase sedation. Use Caution/Monitor.arformoterolchlordiazepoxide increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazolechlordiazepoxide and aripiprazole both increase sedation. Use Caution/Monitor.armodafinilchlordiazepoxide increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.asenapineasenapine and chlordiazepoxide both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and chlordiazepoxide both increase sedation. Use Caution/Monitor.atazanaviratazanavir increases levels of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.avapritinibavapritinib and chlordiazepoxide both increase sedation. Use Caution/Monitor.azelastineazelastine and chlordiazepoxide both increase sedation. Use Caution/Monitor.baclofenchlordiazepoxide and baclofen both increase sedation. Use Caution/Monitor.belladonna and opiumchlordiazepoxide and belladonna and opium both increase sedation. Use Caution/Monitor.belzutifanbelzutifan will decrease the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. benperidolchlordiazepoxide and benperidol both increase sedation. Use Caution/Monitor.benzphetaminechlordiazepoxide increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.bosentanbosentan will decrease the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.brexanolonebrexanolone, chlordiazepoxide. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and chlordiazepoxide both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and chlordiazepoxide both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and chlordiazepoxide both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and chlordiazepoxide both increase sedation. Use Caution/Monitor.buprenorphinechlordiazepoxide and buprenorphine both increase sedation. Use Caution/Monitor.buprenorphine buccalchlordiazepoxide and buprenorphine buccal both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantchlordiazepoxide increases toxicity of buprenorphine subdermal implant by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Studies have shown that the combination of benzodiazepines and buprenorphine altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists. There have been postmarketing reports of coma and death with coadministration of buprenorphine and benzodiazepines. In many, but not all of these cases, buprenorphine was misused by self-injection. If a benzodiazepine must be used for an indication other than seizures, lower the benzodiazepine initial dose and cautiously titrate to clinical response.buprenorphine, long-acting injectionchlordiazepoxide increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.butabarbitalbutabarbital and chlordiazepoxide both increase sedation. Use Caution/Monitor.butalbitalbutalbital and chlordiazepoxide both increase sedation. Use Caution/Monitor.butorphanolchlordiazepoxide and butorphanol both increase sedation. Use Caution/Monitor.caffeinechlordiazepoxide increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbamazepinecarbamazepine will decrease the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.carbinoxaminecarbinoxamine and chlordiazepoxide both increase sedation. Use Caution/Monitor.carisoprodolchlordiazepoxide and carisoprodol both increase sedation. Use Caution/Monitor.cenobamatecenobamate, chlordiazepoxide. Either increases effects of the other by sedation. Use Caution/Monitor.ceritinibceritinib will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.chloral hydratechlordiazepoxide and chloral hydrate both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and chlordiazepoxide both increase sedation. Use Caution/Monitor.chlorpromazinechlordiazepoxide and chlorpromazine both increase sedation. Use Caution/Monitor.chlorzoxazonechlordiazepoxide and chlorzoxazone both increase sedation. Use Caution/Monitor.cimetidinecimetidine increases levels of chlordiazepoxide by decreasing metabolism. Use Caution/Monitor.cinnarizinecinnarizine and chlordiazepoxide both increase sedation. Use Caution/Monitor.clarithromycinclarithromycin will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.clemastineclemastine and chlordiazepoxide both increase sedation. Use Caution/Monitor.clobazamchlordiazepoxide, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipraminechlordiazepoxide and clomipramine both increase sedation. Use Caution/Monitor.clonazepamchlordiazepoxide and clonazepam both increase sedation. Use Caution/Monitor.clonidineclonidine, chlordiazepoxide. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects.clorazepatechlordiazepoxide and clorazepate both increase sedation. Use Caution/Monitor.clozapinechlordiazepoxide and clozapine both increase sedation. Use Caution/Monitor.cobicistatcobicistat will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.codeinechlordiazepoxide and codeine both increase sedation. Use Caution/Monitor.crofelemercrofelemer increases levels of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.cyclizinecyclizine and chlordiazepoxide both increase sedation. Use Caution/Monitor.cyclobenzaprinechlordiazepoxide and cyclobenzaprine both increase sedation. Use Caution/Monitor.cyproheptadinecyproheptadine and chlordiazepoxide both increase sedation. Use Caution/Monitor.dabrafenibdabrafenib will decrease the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.dantrolenechlordiazepoxide and dantrolene both increase sedation. Use Caution/Monitor.daridorexantchlordiazepoxide and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darunavirdarunavir increases levels of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Potential for increased toxicity. Use alternatives if available. Consider